News

Dual Therapy’s One-Two Punch Knocks Out Drug-Resistant Lung Cancer

Dual Therapy’s One-Two Punch Knocks Out Drug-Resistant Lung Cancer

April 2, 2015

Capitalizing on a rare opportunity to thoroughly analyze a tumor from a lung cancer patient who had developed resistance to targeted drug treatment, UC San Francisco scientists identified a biological escape hatch that explains the resistance, and developed a strategy in mice for shutting it down.
 
Immunotherapy: A Field Whose Day Has Come

Immunotherapy: A Field Whose Day Has Come

April 1, 2015

In closing the 2015 UCSF Helen Diller Family Comprehensive Cancer Center Symposium, President Alan Ashworth, PhD, FRS, counted himself among those who might once have underappreciated the full potential of cancer immunotherapy. “But,” he declared, “it is clearly a field whose day has come.” He ...
UCSF to Study Benefits of Personal Approach to Breast Cancer Screening

UCSF to Study Benefits of Personal Approach to Breast Cancer Screening

March 25, 2015

A research team at UC San Francisco has won a five-year award of $14.1 million from the Patient-Centered Outcomes Research Institute (PCORI) to investigate whether a personalized approach to breast cancer screening is as safe and effective as annual mammograms.
 
Two UCSF Chancellors Emeriti to Appear in PBS Cancer Documentary

Two UCSF Chancellors Emeriti to Appear in PBS Cancer Documentary

March 24, 2015

UC San Francisco chancellors emeriti J. Michael Bishop, MD, and Susan Desmond-Hellmann, MD, MPH, will appear next week in a Ken Burns-produced PBS documentary called “Cancer: The Emperor of All Maladies,” which is based on the Pulitzer Prize-winning book of the same name by Columbia University oncologist Siddhartha Mukherjee, MD, PhD.

Childhood Leukemia Study Reveals Disease Subtypes, New Treatment Option

Childhood Leukemia Study Reveals Disease Subtypes, New Treatment Option

March 9, 2015

A new study of acute lymphoblastic leukemia (ALL), a blood cancer that primarily affects young children, has revealed that the disease has two distinct subtypes, and provides preliminary evidence that about 13 percent of ALL cases may be successfully treated with targeted drugs that have proved highly effective in the treatment of lymphomas in adults.

Protein May Be Key to Cancer’s Deadly Resurgences

Protein May Be Key to Cancer’s Deadly Resurgences

March 2, 2015

Tumor recurrence following a period of remission is the main cause of death in cancer. The ability of cancer cells to remain dormant during and following therapy, only to be reactivated at a later time, frequently with greater aggressiveness, is one of the least-understood aspects of the disease.